{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"Progression of Disease (POD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"as assessed by RECIST criteria","groups":[{"description":"Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas","id":"OG000","title":"Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Objective Response","type":"PRIMARY","unitOfMeasure":"participants"}